Merck & Co., Inc. MRK
Healthcare · Drug Manufacturers - General · United States · S&P 500
Based on the available data, Merck & Co., Inc. gets an algorithmic score of 58/100. It trades at 149.28 $, with a bullish technical trend (RSI 58.9) and 30.3% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Low beta (0.28): defensive profile.
Weaknesses
- —
Fundamentals
| P/E | 119.42 |
| Forward P/E | 15.66 |
| PEG | 2.70 |
| P/B | 8.79 |
| EV/EBITDA | 14.38 |
| P/S | 5.53 |
| ROE % | 6.96 |
| ROA % | 11.87 |
| Gross margin % | 75.90 |
| Operating margin % | -0.24 |
| Net margin % | 4.77 |
| Revenue growth % (y/y) | 5.10 |
| Revenue CAGR % | 3.12 |
| Earnings CAGR % | 7.93 |
| Debt/Equity % | 128.41 |
| Current ratio | 1.32 |
| FCF yield % | 3.36 |
| Dividend yield % | 2.28 |
| Payout % | 268.80 |
Returns
| 1 month | +1.2 % |
| 3 months | +16.9 % |
| 6 months | +28.1 % |
| YTD | +43.1 % |
| 1 year | +95.6 % |
| 3 years | +53.8 % |
| 5 years | +141.7 % |
Risk
| 1-year volatility | 30.3 % |
| Beta | 0.28 |
| 5-year max drawdown | -43.4 % |
| Sharpe 1A | 2.23 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.